Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists
Authors:
- 20 February 2007
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 375 (2) , 133-144
Abstract
Antagonists of adenosine A2A receptors (A2A-antagonists) with different chemical structures have been developed by several pharmaceutical companies for the potential treatment of Parkinson’s disease. Pharmacological characterization of these antagonists was incomplete, and different assay conditions were used in different labs. Therefore, we characterized the potencies, selectivities, and pharmacokinetic profiles of six prototypical A2A-antagonists. Displacements of [3H]MSX-2 and of [3H]CGS21680 binding to the human cloned and rat A2A receptors were performed. The rank order of potency of antagonists to displace [3H]MSX-2 binding to the human A2A was SCH58261 ≥ Biogen-34 ≥ Ver-6623 ≥ MSX-2 > KW-6002 > > DMPX. For the rat striatal A2A, the order of potency was Biogen-34 ≥ SCH58261 ≥ Ver-6623 ≥ MSX-2 ≥ KW-6002 > > DMPX. SCH58261 was the most potent antagonist of the human A2A with a K i value of 4 nM, whereas Biogen-34 was the most potent antagonist of the rat A2A with a K i value of 1.2 nM. Similar results were obtained from cAMP assays. Selectivities of A2A-antagonists were determined using radioligands [3H]DPCPX, [3H]ZM241385, and [125I]-AB-MECA for A1, A2B, and A3 receptors, respectively. KW-6002 and Biogen-34 exhibited the highest selectivity for A2A vs A1 (human and rat), respectively. The pharmacokinetic profiles of antagonists were evaluated in vivo in rats. DMPX and KW-6002 had the greatest oral bioavailability. In contrast, SCH58261, MSX-2, and Ver-6623 had low or poor oral bioavailability. In summary, SCH58261, Biogen-34, MSX-2, and Ver-6623 had high affinities for both human and rat A2A receptors, with reasonable selectivity for A2A over A1 and A2B receptors. They are suitable as A2A-antagonists for in vitro pharmacological studies. Among the six A2A-antagonists, KW-6002 is the best for use in in vivo animal studies, particularly for a CNS target, based on its bioavailability, half life, and brain penetration.Keywords
This publication has 30 references indexed in Scilit:
- Studies on adenosine A2a receptor antagonists: comparison of three core heterocyclesBioorganic & Medicinal Chemistry Letters, 2004
- Piperazine Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A2aReceptor AntagonistsJournal of Medicinal Chemistry, 2004
- Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's DiseaseThe Journal of Organic Chemistry, 2004
- Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in ratsSynapse, 2003
- Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell lineBritish Journal of Pharmacology, 2001
- Adenosine A2A antagonists with potent anti-cataleptic activityBioorganic & Medicinal Chemistry Letters, 1997
- Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]‐SCH 58261British Journal of Pharmacology, 1997
- Pharmacodynamics of ZM 241385, a Potent A2a Adenosine Receptor Antagonist, after Enteric Administration in Rat, Cat and DogJournal of Pharmacy and Pharmacology, 1996
- 3,7-Dimethyl-1-propargylxanthine: A potent and selective in vivo antagonist of adenosine analogsLife Sciences, 1988
- Analogs of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A1-adenosine receptors by aryl substituentsJournal of Medicinal Chemistry, 1986